Literature DB >> 23326194

Personalized nanomedicine: future medicine for cancer treatment.

Farooq A Shiekh.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23326194      PMCID: PMC3544349          DOI: 10.2147/IJN.S41525

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


× No keyword cloud information.
Cancer as a grave disease is becoming a larger health problem,1 and the medicines used as treatments have clear limitations.2–4 Chemotherapy, radiation, and surgery, all of which are drastic treatments, wreak havoc on healthy cells and tissues as well as cancerous ones.5–7 Pathophysiologically, there are more than 200 types of cancers,8,9 each with many variants.10 Some are aggressive, some are not; some are easily treated, and others are always fatal.11 Unlike previous “revolutions” in the “war” on cancer that raised hope, nanomedicine is not just one more tool, it is an entire field, and the science in this area is burgeoning, and benefiting from use of modern cutting edge molecular tools.12–14 These breakthrough advancements have radically changed the perception of future medicine. Importantly, they are enabling landmark research to combine all advances, creating nanosized particles that contain drugs targeting cell surface receptors and other potent molecules designed to kill cancerous cells.15–19 If there is a case to be made for personalized medicine, cancer is it. For example, the current literature reveals the need for a great scientific effort to be made in this field.20–22 However, new paradigms are needed to interpret toxicogenomic and nanotoxicological data in order to predict drug toxicities and gain a more indepth understanding of the mechanisms of toxicity, so that more specific therapeutic targets which are essentially devoid of side effects could be selected.23,24 The future of nanomedicine and the opportunity to eliminate the suffering and death due to cancer will hinge on our ability to confront cancer at its molecular level.25 Nevertheless, there are many outstanding questions that remain unanswered. A revolution in nanoscience is now heralding a long-awaited era of personalized cancer treatment that is now much closer than ever before. Personalized medicine will ensure that such drugs are given only to patients who stand to benefit from them. If that happens, nanobased drugs will be at least less toxic than today’s armamentarium for cancer. If they work as intended, they should also prove to be far more effective.
  25 in total

1.  Toxicogenomics gains impetus.

Authors:  Diane Gershon
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

2.  Materials and biology. Nanotechnology takes aim at cancer.

Authors:  Robert F Service
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

3.  Nanotechnology. Small things and big changes in the developing world.

Authors:  Mohamed H A Hassan
Journal:  Science       Date:  2005-07-01       Impact factor: 47.728

Review 4.  Epidemiology - identifying the causes and preventability of cancer?

Authors:  Graham A Colditz; Thomas A Sellers; Edward Trapido
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

Review 5.  Molecular targets for cancer chemoprevention.

Authors:  William N William; John V Heymach; Edward S Kim; Scott M Lippman
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

6.  Seven challenges for nanomedicine.

Authors:  Wendy R Sanhai; Jason H Sakamoto; Richard Canady; Mauro Ferrari
Journal:  Nat Nanotechnol       Date:  2008-05       Impact factor: 39.213

7.  Big opportunities in a small world.

Authors:  Virginia Gewin
Journal:  Nature       Date:  2009-07-23       Impact factor: 49.962

8.  Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel R Greenwald; Erkki Ruoslahti
Journal:  Science       Date:  2010-04-08       Impact factor: 47.728

9.  Recurrence after mastectomy for ductal carcinoma in situ.

Authors:  Laura N Godat; Janet K Horton; Perry Shen; John H Stewart; Stacy Wentworth; Edward A Levine
Journal:  Am Surg       Date:  2009-07       Impact factor: 0.688

10.  Predicting enhanced cell killing through PARP inhibition.

Authors:  Julie K Horton; Samuel H Wilson
Journal:  Mol Cancer Res       Date:  2012-11-27       Impact factor: 5.852

View more
  7 in total

Review 1.  Radiolabeled theranostics: magnetic and gold nanoparticles.

Authors:  Saeideh Same; Ayuob Aghanejad; Sattar Akbari Nakhjavani; Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2016-09-30

2.  Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma.

Authors:  Ewelina Zielinska; Agata Zauszkiewicz-Pawlak; Michal Wojcik; Iwona Inkielewicz-Stepniak
Journal:  Oncotarget       Date:  2017-11-20

3.  Editor's choice: recent research highlights from the International Journal of Nanomedicine.

Authors:  Farooq A Shiekh; Abdul-Rahman M Abu-Izzah; Vivian J Lee; Syed Mudassar
Journal:  Int J Nanomedicine       Date:  2017-06-19

4.  Automatic Echographic Detection of Halloysite Clay Nanotubes in a Low Concentration Range.

Authors:  Francesco Conversano; Paola Pisani; Ernesto Casciaro; Marco Di Paola; Stefano Leporatti; Roberto Franchini; Alessandra Quarta; Giuseppe Gigli; Sergio Casciaro
Journal:  Nanomaterials (Basel)       Date:  2016-04-11       Impact factor: 5.076

5.  Size dependent anti-invasiveness of silver nanoparticles in lung cancer cells.

Authors:  Yu Mei Que; Xiao Qing Fan; Xiao Juan Lin; Xiao Li Jiang; Ping Ping Hu; Xiao Yong Tong; Qun You Tan
Journal:  RSC Adv       Date:  2019-07-05       Impact factor: 4.036

6.  Targeted nanotherapeutics in cancer.

Authors:  Farooq A Shiekh
Journal:  Int J Nanomedicine       Date:  2014-03-26

7.  Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer.

Authors:  Enrique Niza; María Del Mar Noblejas-López; Iván Bravo; Cristina Nieto-Jiménez; José Antonio Castro-Osma; Jesús Canales-Vázquez; Agustín Lara-Sanchez; Eva M Galán Moya; Miguel Burgos; Alberto Ocaña; Carlos Alonso-Moreno
Journal:  Nanomaterials (Basel)       Date:  2019-12-16       Impact factor: 5.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.